SCHEMBL4764423

SCHEMBL4764423

CCOc1nc2cccc(C(=O)NC)c2n1Cc1ccc(-c2ccccc2S(=O)(=O)Nc2noc(C)c2C)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EDNRA P25101 9/20 0.48
AGTR2 P50052 2/20 0.48
AGTR1 P30556 2/20 0.48
ABCB11 O95342 1/20 0.48
EGFR P00533 1/20 0.48
ERBB2 P04626 1/20 0.48
CYP3A4 P08684 1/20 0.48
ADORA3 P0DMS8 1/20 0.48
CYP2C9 P11712 1/20 0.48
ADRB3 P13945 1/20 0.48
ADRA2B P18089 1/20 0.48
SLC6A2 P23975 1/20 0.48
TBXAS1 P24557 1/20 0.48
HTR2C P28335 1/20 0.48
PPARG P37231 1/20 0.48
HTR2B P41595 1/20 0.48
PDE3A Q14432 1/20 0.48
LTB4R2 Q9NPC1 1/20 0.48
NAE1 Q13564 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4774374 0.93 AGTR2 (0.57) EDNRAAGTR2AGTR1ABCB11EGFR
SCHEMBL4791671 0.92 AGTR2 (0.51) EDNRAAGTR2AGTR1ABCB11EGFR
SCHEMBL4774383 0.91 EDNRA (0.48) EDNRAAGTR2AGTR1ABCB11EGFR
SCHEMBL4769543 0.90 EDNRA (0.56) EDNRAAGTR2AGTR1
SCHEMBL7847923 0.89 EDNRA (0.61) EDNRAAGTR2AGTR1
SCHEMBL4769561 0.89 EDNRA (0.62) EDNRAAGTR1
SCHEMBL4770094 0.83 EDNRA (0.56) EDNRAAGTR1
SCHEMBL4771827 0.83 EDNRA (0.58) EDNRA
SCHEMBL4769517 0.82 EDNRA (0.58) EDNRAAGTR2AGTR1
SCHEMBL4763879 0.81 EDNRA (0.63) EDNRAAGTR2AGTR1ABCB11EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2002837-A1 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2008-12-17 EP claimed
US-20040127515-A1 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists PHARMACOPEIA, LLC 2004-07-01 US claimed
US-20040106833-A1 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists PHARMACOPEIA, LLC 2004-06-03 US claimed
US-20020143024-A1 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists PHARMACOPEIA, LLC 2002-10-03 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127515-A1 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists EDNRB, AGTR2, EDNRA EDNRA 3/4885AGTR2 2/4885AGTR1 4/4885
US-20020143024-A1 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists EDNRB, AGTR2, EDNRA EDNRA 3/4885AGTR2 2/4885AGTR1 4/4885
US-20040106833-A1 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists EDNRB, AGTR2, EDNRA EDNRA 3/4885AGTR2 2/4885AGTR1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.